| Literature DB >> 27990138 |
Rizwana Parveen Rani1, Marimuthu Anandharaj2, Subramani Hema1, Ramasamy Deepika1, Abraham David Ravindran1.
Abstract
This study focuses on isolation, screening, and characterization of novel probiotics from gastrointestinal tract of free-range chicken (Gallus gallus domesticus). Fifty seven colonies were isolated and three isolates (FR4, FR9, and FR12) were selected and identified as Lactobacillus gasseri FR4, Bacillus tequilensis FR9, and L. animalis FR12 by 16S rRNA sequencing. Three strains were able to survive in stimulated acidic and bile conditions and inhibit the growth of pathogens. Especially, FR9 exhibited maximum inhibition against Listeria monocytogenes and none of them exhibited hemolytic activity. Native-PAGE revealed the presence of low molecular weight (3.4-5.0 KDa) antimicrobial peptide. The peptide was further purified by Sephadex G-50 column and RP-HPLC using C18 column. N-terminal amino acid sequencing of antimicrobial peptide showed 100% consensus to antilisterial peptide Subtilosin A and SboA gene was amplified from FR9 genome. FR9 showed maximum aggregation activity, exopolysaccharide production (85.46 mg/L) and cholesterol assimilation (63.12 ± 0.05 μg/mL). Strong adhesion property (12.6%) and pathogen invasion protection ability was revealed by B. tequilensis FR9 towards HCT-116 human colon carcinoma cell line. This is the first study to demonstrate antilisterial Subtilosin A production of B. tequilensis. Our results indicate that B. tequilensis FR9 strain furnish the essential characteristics of a potential probiotics and might be incorporated into human and animal food supplements.Entities:
Keywords: Bacillus tequilensis; Subtilosin A; adhesion assay; bacteriocin; cholesterol reduction; probiotic
Year: 2016 PMID: 27990138 PMCID: PMC5133052 DOI: 10.3389/fmicb.2016.01910
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Gene specific primers used for the amplification of bacteriocin genes in this study.
| Bacteriocin gene | Bacterial source | Sequence (5′ to 3′) | Expected amplicon size (bp) | Reference |
|---|---|---|---|---|
| Cerein | Cer7B-F:CCCTCTATATGAGGGAGTAA | 416 | This study | |
| Cer7B-R: GTTTAATAATCTATACAGTA | ||||
| Subtilosin A | SboA-F: CATATGAAAAAAGCTGTCATTG | 394 | This study | |
| SboA-R: AAGCTTTTACCCCCATAGACC | ||||
| Thuricin H | Thu17-F: AGTATGTGCAGCATGTTCTG | 555 | This study | |
| Thu17-R: ATAAACACTCTCACATTTTT | ||||
| Lichenicidin | LanA2-F: ATGTCAAAAAAGGAAATGAT | 225 | This study | |
| LanA2-R: TTAGTTACAGCTTGGCATGC | ||||
| Ericins | EriSa-F: GTGACTAATATGTCAAAGTT | 171 | This study | |
| EriSa-R: TCAGCACTTAGCAAATGTTG | ||||
| albA | albA-F:CTAAATAAGCTGGACCACGTCTT | 1347 | This study | |
| albA-R: TTGTTTATAGAGCAGATGTTTCC |
Effect of pH on the viability of FR4, FR9, and FR12 strains, incubated at various pH range (7, 1, 2, and 3), values are expressed as log CFU/mL, survival percentage and regression coefficient.
| Strains | Controla (log CFU/mL) | pH 1.0 (log CFU/mL) | SRb (%) | pH 2.0 (log CFU/mL) | SR (%) | pH 3.0 (log CFU/mL) | SR (%) | Multiple R |
|---|---|---|---|---|---|---|---|---|
| FR4 | 6.47 | 1.59 | 24.57 | 3.71 | 57.34 | 5.32 | 82.22 | 0.857 |
| FR9 | 6.83 | 2.38 | 34.85 | 4.86 | 71.15 | 5.66 | 82.86 | 0.904 |
| FR12 | 7.86 | 1.68 | 21.37 | 3.46 | 44.02 | 6.36 | 80.91 | 0.826 |
Effect of bile salt on the viability of FR4, FR9 and FR12 strains, incubated at various bile salt concentrations (0.3% to 0.5%).
| Strains | 3 h | 5 h | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Controla (log CFU/mL) | 0.3% bile salts (log CFU/mL) | SRb (%) | 0.5% bile salts (log CFU/mL) | SR (%) | Multiple R | Controla (log CFU/mL) | 0.3% bile salts (log CFU/mL) | SRb (%) | 0.5% bile salts (log CFU/mL) | SR (%) | Multiple R | |
| FR4 | 6.53 | 5.32 | 81.47 | 4.26 | 65.23 | 0.758 | 7.78 | 5.78 | 74.29 | 4.34 | 55.78 | 0.864 |
| FR9 | 8.06 | 6.86 | 85.11 | 5.93 | 73.57 | 0.903 | 8.61 | 6.46 | 75.02 | 5.93 | 68.87 | 0.911 |
| FR12 | 7.76 | 5.76 | 74.22 | 4.90 | 63.14 | 0.812 | 8.43 | 5.63 | 66.78 | 4.56 | 54.09 | 0.791 |
Antimicrobial activity of cell free culture supernatants (CFCS) of L. gasseri FR4, B. tequilensis FR9, and L. animalis FR12 strains against various pathogens (inhibition zone in mm ± standard deviation).
| Bacterial Isolates | FR4 | AU | FR9 | AU | FR12 | AU |
|---|---|---|---|---|---|---|
| 9.50 ± 0.31cd | 542.50 | 13.33 ± 0.13e | 1416.88 | 11.81 ± 0.58cd | 1034.76 | |
| 11.20 ± 0.13e | 894.40 | 12.02 ± 0.42e | 1084.80 | 10.09 ± 0.61e | 658.08 | |
| 10.90 ± 0.27bc | 828.10 | 11.40 ± 0.12b | 939.60 | 10.90 ± 0.28b | 658.08 | |
| Diameter mean (Gram-negative) | 10.53 ± 0.23 | 748.80 | 12.25 ± 0.22 | 1140.62 | 10.93 ± 0.49 | 834.64 |
| 7.36 ± 0.19bc | 181.69 | 9.18 ± 0.18b | 482.72 | 8.10 ± 0.07b | 296.10 | |
| 11.00 ± 0.81bc | 850 | 13.20 ± 0.31cd | 1382.40 | 9.00 ± 1.15b | 450 | |
| 14.66 ± 0.67c | 1789.15 | 19.00 ± 0.18cd | 3250 | 15.09 ± 0.86b | 1917 | |
| 6.33 ± 0.19cd | 40.68 | 7.12 ± 0.24e | 146.94 | NS | 0 | |
| Diameter mean (Gram-positive) | 10.92 ± 0.37 | 832.46 | 12.59 ± 0.29 | 1225.08 | 8.04 ± 0.52 | 286.41 |
| 14.00 ± 0.29f | 1600 | 17.01 ± 0.46f | 2533.40 | 9.36 ± 0.64f | 516 | |
| 12.00 ± 0.25f | 1080 | 13.00 ± 0.51f | 1330 | 11.00 ± 0.48f | 850 | |
| 1.07 ± 0.12a | 125.80 | 6.98. ± 0.32a | 127.20 | 6.63 ± 0.45a | 79.56 |
β-glucosidase activity and exopolysaccharide (EPS) production by bacterial isolates.
| Bacterial isolates | β-glucosidase activity (μmol/ml/min) | EPS production (mg/mL) |
|---|---|---|
| FR4 | 5.38 ± 0.26 | 64.32 ± 0.18 |
| FR9 | 7.65 ± 0.38 | 85.46 ± 0.24 |
| FR12 | 4.29 ± 0.17 | 43.49 ± 1.56 |